Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/04/25
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 07/28/25
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS PipelineGlobeNewsWire • 07/21/25
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4GlobeNewsWire • 07/09/25
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21GlobeNewsWire • 07/07/25
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness MonthGlobeNewsWire • 06/20/25
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025GlobeNewsWire • 06/11/25
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.GlobeNewsWire • 05/27/25
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with BlackstoneGlobeNewsWire • 05/13/25
Prediction: These 2 Stocks Will Outperform the Market in the Next Five YearsThe Motley Fool • 05/12/25
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/YZacks Investment Research • 05/06/25
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/05/25
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/05/25